Akebia Therapeutics Announces Top-Line Results Of Phase 4 IMPACT Study Of Auryxia For In-Center And Home Dialysis Patients
Portfolio Pulse from Happy Mohamed
Akebia Therapeutics, Inc. (NASDAQ:AKBA) has announced the top-line results from its Phase 4 IMPACT study of Auryxia, a primary phosphate-lowering therapy for adult patients with chronic kidney disease (CKD) on dialysis. The study, sponsored by U.S. Renal Care Kidney Research in collaboration with Akebia, showed a statistically significant difference in mean monthly erythropoiesis-stimulating agent (ESA) use and a non-significant difference in mean monthly intravenous (IV) iron use. Serious adverse events occurred in 39% of patients receiving Auryxia and 59% in those receiving standard of care (SOC).
June 29, 2023 | 12:12 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
The results of the IMPACT study could potentially impact the use of Auryxia in adult patients with hyperphosphatemia on dialysis, which could affect Akebia Therapeutics' market position and revenues.
The results of the IMPACT study showed a significant difference in ESA use, which could potentially lead to increased use of Auryxia in the treatment of adult patients with CKD on dialysis. However, the occurrence of serious adverse events in 39% of patients receiving Auryxia could potentially impact its adoption. The impact on Akebia Therapeutics' stock price will depend on how the market perceives these results and their potential implications for the company's future revenues and market position.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100